Trial Profile
A Multicenter, Uncontrolled, Open-label Trial to Evaluate the Safety of Extended Treatment With Brexpiprazole (OPC-34712) to Patients With Agitation Associated With Dementia of the Alzheimer's Type
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Brexpiprazole (Primary)
- Indications Agitation
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical
- 12 Jan 2022 Status changed from recruiting to completed.
- 28 Feb 2021 Planned End Date changed from 1 May 2021 to 1 Feb 2022.
- 28 Feb 2021 Planned primary completion date changed from 1 May 2021 to 1 Feb 2022.